Brain Tumor Treatments: Less-Toxic

Sponsored By

Please Click On The Above Banner For More Details

Search Term: Less-Toxic
Please scroll down past the trials to see pages on this site about this topic!


	Previous 25 Showing Treatment 26 to 50 of 360 Next 25	Location	Last Updated

Details	A Pharmacokinetic and Phase 2 Study of Sunitinib Malate in Recurrent Malignant Gliomas	Bethesda, MD USA	04/21/2009

Details	A Pharmacokinetic and Phase 2 Study of Sunitinib Malate in Recurrent Malignant Gliomas	Cincinnati,, OH USA	04/21/2009

Details	A Pharmacokinetic and Phase 2 Study of Sunitinib Malate in Recurrent Malignant Gliomas	Columbus, OH USA	04/21/2009

Details	A Pharmacokinetic and Phase 2 Study of Sunitinib Malate in Recurrent Malignant Gliomas	Toronto, Ontario, CANADA	04/21/2009

Details	A Feasibility Assessment and a Phase I/II Trial of MLN518 (Tandutinib) for Treatment of Patients with Recurrent Glioblastoma	Winston-Salem, NC USA	04/21/2009

Details	A Feasibility Assessment and a Phase I/II Trial of MLN518 (Tandutinib) for Treatment of Patients with Recurrent Glioblastoma	Tampa, FL USA	04/21/2009

Details	A Feasibility Assessment and a Phase I/II Trial of MLN518 (Tandutinib) for Treatment of Patients with Recurrent Glioblastoma	Boston, MA USA	04/21/2009

Details	A Feasibility Assessment and a Phase I/II Trial of MLN518 (Tandutinib) for Treatment of Patients with Recurrent Glioblastoma	Baltimore, MD USA	04/21/2009

Details	A Feasibility Assessment and a Phase I/II Trial of MLN518 (Tandutinib) for Treatment of Patients with Recurrent Glioblastoma	Detroit, MI USA	04/21/2009

Details	A Feasibility Assessment and a Phase I/II Trial of MLN518 (Tandutinib) for Treatment of Patients with Recurrent Glioblastoma	Atlanta, GA USA	04/21/2009

Details	A Feasibility Assessment and a Phase I/II Trial of MLN518 (Tandutinib) for Treatment of Patients with Recurrent Glioblastoma	Cleveland, OH USA	04/21/2009

Details	A Feasibility Assessment and a Phase I/II Trial of MLN518 (Tandutinib) for Treatment of Patients with Recurrent Glioblastoma	Bethesda, MD USA	04/21/2009

Details	A Feasibility Assessment and a Phase I/II Trial of MLN518 (Tandutinib) for Treatment of Patients with Recurrent Glioblastoma	Philadelphia, PA USA	04/21/2009

Details	A Feasibility Assessment and a Phase I/II Trial of MLN518 (Tandutinib) for Treatment of Patients with Recurrent Glioblastoma	Birmingham, AL USA	04/21/2009

Details	An Open Label Dose Escalation Safety Study of Convection-Enhanced Delivery of IL13-PE38QQR in Patients With Progressive Pediatric Diffuse Infiltrating Brainstem Glioma and Supratentorial High-Grade Glioma	Bethesda, MD USA	04/15/2009

Details	Phase III double blind, placebo controlled study of donepezil in irradiated brain tumor patients	Houston, TX USA	04/03/2009

Details	Bevacizumab (Avastin) and Irinotecan (CPT-11) in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma	Philadelphia, PA USA	11/08/2008

Details	Bevacizumab (Avastin) and Irinotecan (CPT-11) in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma	Memphis, TN USA	11/08/2008

Details	Bevacizumab (Avastin) and Irinotecan (CPT-11) in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma	Durham, NC USA	11/08/2008

Details	Bevacizumab (Avastin) and Irinotecan (CPT-11) in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma	Seattle, WA USA	11/08/2008

Details	Bevacizumab (Avastin) and Irinotecan (CPT-11) in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma	Chicago, IL USA	11/08/2008

Details	Bevacizumab (Avastin) and Irinotecan (CPT-11) in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma	Pittsburgh, PA USA	11/08/2008

Details	Bevacizumab (Avastin) and Irinotecan (CPT-11) in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma	Boston, MA USA	11/08/2008

Details	Bevacizumab (Avastin) and Irinotecan (CPT-11) in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma	San Francisco, CA USA	11/08/2008

Details	Bevacizumab (Avastin) and Irinotecan (CPT-11) in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma	Washington, DC USA	11/08/2008

(Relevance) Page Title - click title to go to the page!

Translate this pageMicrosoftÂ® Translator

Copyright (c) 1993 - 2009 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740

Website Design By